

FIG.1 IL-18 polypeptides**FIG.1A Human IL-18 polypeptide sequence**

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn
1 5 10 15
Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp
20 25 30
Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile
35 40 45
Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile
50 55 60
Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile
65 70 75 80
Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys
85 90 95
Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys
100 105 110
Met Gln Phe Glu Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu
115 120 125
Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu
130 135 140
Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp
145 150 155

FIG.1B Murine IL-18 polypeptide sequence

Asn	Phe	Gly	Arg	Leu	His	Cys	Thr	Thr	Ala	Val	Ile	Arg	Asn	Ile	Asn
1															15
Asp	Gln	Val	Leu	Phe	Val	Asp	Lys	Arg	Gln	Pro	Val	Phe	Glu	Asp	Met
															30
Thr	Asp	Ile	Asp	Gln	Ser	Ala	Ser	Glu	Pro	Gln	Thr	Arg	Leu	Ile	Ile
															45
Tyr	Met	Tyr	Lys	Asp	Ser	Glu	Val	Arg	Gly	Leu	Ala	Val	Thr	Leu	Ser
															50
Val	Lys	Asp	Ser	Lys	Met	Ser	Thr	Leu	Ser	Cys	Lys	Asn	Lys	Ile	Ile
															65
Ser	Phe	Glu	Glu	Met	Asp	Pro	Pro	Glu	Asn	Ile	Asp	Asp	Ile	Gln	Ser
															85
Asp	Leu	Ile	Phe	Phe	Gln	Lys	Arg	Val	Pro	Gly	His	Asn	Lys	Met	Glu
															100
Phe	Glu	Ser	Ser	Leu	Tyr	Glu	Gly	His	Phe	Leu	Ala	Cys	Gln	Lys	Glu
															115
Asp	Asp	Ala	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Asp	Glu	Asn	Gly	Asp	
															130
Lys	Ser	Val	Met	Phe	Thr	Leu	Thr	Asn	Leu	His	Gln	Ser			
															145
															150
															155



FIG.2 In vivo tumour growth in control non Tg mice**FIG.2A - IL-18 1 µg + vaccination with E7 + AS02****FIG.2B - IL-18 100 µg + vaccination with E7 + AS02**



FIG.3 In vivo tumour growth in E7 Tg mice**FIG.3A - IL-18 1 µg + vaccination with E7 + AS02****FIG.3B - IL-18 100 µg + vaccination with E7 + AS02**

FIG.4 Antibody response and isotypic profile in control non Tg mice**FIG.4A – Antibody response**

Total Ig response (standard titers are expressed in EU/ml).



**FIG.4B – Isotypic profile**

FIG.5 Antibody response and isotypic profile in E7 Tg mice**FIG.5A – Antibody response**

Total Ig response (standard titers are expressed in EU/ml).



**FIG.5A – Isotypic profile**

FIG. 6 In vivo tumour growth in TCI Her2 therapeutic model